Negrier S, Mercatello A, Coronel B, Ravaud A, Merrouche Y, Bret M, Lanier F, Moskovtchenko J F, Philip T
Département de Médecine Carcinologique, Centre Léon Bérard, Lyon.
J Chir (Paris). 1992 Jun-Jul;129(6-7):292-6.
Like interferon-alpha, interleukin 2 (IL2) is active on metastatic kidney cancers, which are regarded as chemoresistant tumors. Out of 20 to 30% objective responses, 5 to 10% complete remissions are reported with various IL2 delivery schedules. The considerable toxicity is well mastered at present, thus allowing treatment in non-intensive care departments, or even in an ambulatory mode for subcutaneous administration. Even though Interleukin 2 has been authorized for sale in France, optimal mode of administration, the role of the IL2-interferon-alpha combination or the predictive factors of response to treatment still raise many questions.
与干扰素-α一样，白细胞介素2（IL2）对转移性肾癌有活性，转移性肾癌被视为化疗耐药肿瘤。在20%至30%的客观缓解中，不同的IL2给药方案报告有5%至10%的完全缓解。目前，相当大的毒性已得到很好的控制，因此可以在非重症监护病房进行治疗，甚至可以采用皮下给药的门诊模式。尽管白细胞介素2已在法国获批销售，但最佳给药方式、IL2-干扰素-α联合用药的作用或治疗反应的预测因素仍存在许多问题。
